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Abstract
Introduction:  Local  progression  of  papillary  thyroid  carcinoma  (PTC)  after  failure  of  standard
therapies  may  cause  pain,  ulceration,  and  bleeding.  As  patients  are  fully  aware  of  the  tumor
growth, they  might  suffer  high  grade  anxiety.  Electrochemotherapy  (ECT)  is  a  new  local  pallia-
tive treatment  for  skin  metastases  of  malignant  melanoma  or  other  tumors,  including  squamous
head e  neck  cancer  patients.
Objective:  To  evaluate  the  impact  of  ECT  in  patients  with  local  progression  of  PTC.
Methods:  Four  patients  with  local  progression  of  PTC  were  treated  with  ECT  based  on
Bleomycin,  and  evaluated  according  to  tumor  response,  local  pain  and  side  effects.
Results:  In  all  cases,  some  grade  of  tumor  response  was  observed,  lasting  6,  7,  12  and  8  months,
respectively.  Also,  reduction  of  local  pain  and  anxiety  was  registered  in  all  patients.  Tumor
inﬁltrated  skin  necrosis  was  the  only  collateral  effect  of  the  treatment.  ECT  induced  a  tumor
response in  all  PTC  patients  with  improvement  of  symptoms.
Conclusions:  ECT  may  be  an  option  for  local  palliative  treatment  in  PTC  patients  with  local
tumor progression.
©  2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published  by
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Eletroquimioterapia  como  tratamento  paliativo  em  pacientes  com  carcinoma  papilar
da  tireoide
Resumo
Introduc¸ão:  A  progressão  local  do  carcinoma  papilífero  de  tireoide  (CPT)  após  a  falha  da  terapia
de rotina  pode  causar  dor,  ulcerac¸ão  e  sangramento.  Considerando  que  os  pacientes  estão  per-
feitamente  cientes  do  crescimento  tumoral,  podem  apresentar  um  alto  grau  de  ansiedade.
A eletroquimioterapia  (EQT)  é  um  novo  tratamento  paliativo  para  metástases  de  pele  de
melanoma  maligno  ou  de  outros  tumores,  inclusive  em  pacientes  com  carcinoma  escamoso
de cabec¸a  e  pescoc¸o.
Objetivo:  Avaliar  o  impacto  da  EQT  em  pacientes  com  progressão  local  de  CPT.
Método:  Quatro  pacientes  com  progressão  local  de  CPT  foram  tratados  com  EQT  com  base  em
bleomicina,  e  avaliados  em  relac¸ão  ao  grau  de  resposta  tumoral,  dor  local,  efeitos  colaterais.
Resultados:  Em  todos  os  casos,  foi  observado  algum  grau  de  resposta  tumoral,  que  perdurou
por 6,  7,  12  e  8  meses,  respectivamente.  Da  mesma  forma,  foi  registrada  diminuic¸ão  da  dor
local e  da  ansiedade  em  todos  os  pacientes.  Necrose  cutânea  na  inﬁltrac¸ão  tumoral  foi  o  único
efeito colateral  do  tratamento.  EQT  induziu  resposta  tumoral  em  todos  os  pacientes  com  CPT,
com melhora  dos  sintomas.
Conclusões:  EQT  pode  ser  uma  opc¸ão  para  o  tratamento  paliativo  tópico  em  pacientes  com  CPT
com progressão  tumoral  local.
©  2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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Radiological  evaluation  was  performed  at  0,  6,  and  12ntroduction
ocal  relapse  or  regional  neck  metastases  after  failure  of
tandard  therapies  of  papillary  thyroid  carcinoma  (PTC)  are
are.  However,  patients  developing  local  or  regional  tumor
rogression  may  suffer  from  anxiety,  local  pain,  exudation,
r  bleeding.
Electrochemotherapy  (ECT)  is  a  new  experimental  tech-
ology  based  on  increasing  cell  membrane  permeability  of
he  tumor  cells  (electroporation)  to  molecules.  ECT  con-
ists  of  the  administration  of  electric  pulses  in  the  tumor
uring  perfusion  of  chemotherapy  to  facilitate  drug  deliv-
ry  into  malignant  cells.1,2 ECT  is  now  being  used  as  a
alliative  therapy  for  cutaneous  metastases  and  head  and
eck  cancer.3--7 A  recently  published  meta-analysis  of  915
atients  studied  the  results  of  skin-directed  therapy  for  local
utaneous  metastases,  including  electrochemotherapy,  pho-
odynamic  therapy,  radiotherapy,  intralesional  therapy,  and
opical  therapy.8 The  histology  of  primary  tumors  was  mainly
elanoma  and  breast  carcinoma,  and  none  of  them  were
hyroid  carcinoma.  ECT  was  more  active  than  the  other
kin-directed  therapies,  as  a  59%  complete  response  rate
as  reported,  and  transient  local  pain  occurring  in  49%  of
atients  that  resolved  within  a  month  was  the  more  common
ide  effect.
The  authors  present  the  preliminary  results  of  a  pilot
tudy  of  thyroid  cancer  patients  with  progression  of  local
ecurrence  or  neck  metastases  treated  with  ECT.
ethods
nclusion  criteriaatients  resistant  to  radioiodine  and  to  anti-target  agent
orafenib  with  local  tumor  progression  of  PTC  after
w
i
erimary  therapy  (thyroidectomy,  cervical  neck  dissection,
nd  adjuvant  radioiodine),  and  after  treatment  of  the
elapse  (salvage  cervical  surgery  and  radiotherapy)  were
ncluded.  Sorafenib  resistance  was  considered  when  a  20%
ncrease  in  the  sum  of  diameters  of  the  target  lesion  was
bserved.
Additional  inclusion  criteria:  Eastern  Cooperative  Oncol-
gy  Group  performance  status  of  2  or  less,  life  expectancy  of
t  least  three  months,  no  active  respiratory  disease  or  seri-
us  chronic  pulmonary  disease,  absolute  white  blood  count
bove  4000  cells/L, hemoglobin  greater  than  10  g/dL,
latelet  count  above  100,000  L,  and  no  previous  clinical
istory  of  allergy  to  bleomycin.
The  study  was  approved  by  the  Institutional  Review
oard.  Informed  consent  was  obtained  from  all  patients.
reatment
nder  total  anesthesia,  with  an  inspired  oxygen  fraction
FiO2)  of  36%  or  less,  bleomycin,  20  mg/m2 IV  was  admin-
stered  in  a  bolus.  Between  eight  and  28  min  later,  electric
ulses  of  100  s  and  1000  V  were  administered  to  the  target
umor  by  an  electrode  (model  N-30-HG;  IGEA  S.r.l.  --  Carpi,
taly),  powered  by  a  commercial  pulse  generator  for  elec-
roporation  treatments  (CLINIPORATOR;  IGEA  S.r.l.  --  Carpi,
taly).  Tumor  tissue  was  treated  homogeneously,  covering
he  entire  target  volume.
esponse  criteriaeeks  after  ECT,  according  to  Response  Evaluation  Criteria
n  Solid  Tumor  (RECIST)  criteria  (version  1.1).9 Symptom
valuation  of  pain  and  anxiety  was  performed  with  the
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Figure  1  Case  1:  External  aspect  and  CT-scan  of  a  lower  left  cervical  mass  prior  (left  images)  and  after  four  weeks  (right  images)
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Edmonton  Symptom  Assessment  System  before  treatment
and  12  weeks  after  ECT.  The  patients  subjectively  scored
the  intensity  of  these  symptoms  on  a  visual  analogical  scale
(VAS)  between  0  (absence)  and  10  (maximum  intensity).
Toxicity  and  adverse  events  related  to  ECT  were  also
evaluated  at  6,  12,  and  24  h  after  the  procedure.
During  the  follow-up  period,  the  patients  were  evaluated
at  least  every  three  months  or  when  disease  progression  was
observed.
Results
Four  consecutive  patients,  one  male  and  three  females,
were  enrolled  in  the  study.  The  age  ranged  between  51  and
60  years.  The  target  tumor  was  a  large  cervical  mass  in  three
patients  and  skin  metastases  (less  than  2  cm)  in  one.A  clinical  response  was  observed  in  all  four  patients
within  the  ﬁrst  three  weeks  after  ECT  (Fig.  1).  These
ﬁndings  were  consistent  with  the  radiological  evaluation,
showing  partial  response  (PR)  in  two  patients  and  two  cases
D
T
af  disease  stabilization  with  lower  tumor  burden,  but  not
eaching  the  PR  criteria  as  deﬁned  by  RECIST.
The  targeted  lesions’  size  decreased  over  the  next  three
onths  and  remained  without  progression  during  six  to  12
onths  after  the  procedure.  Three  of  the  patients  died
ecause  of  visceral  metastases,  and  there  was  no  disease
rogression  in  the  targeted  lesions  treated  with  ECT.  In  one
ase,  the  patient  died  18  months  after  ECT  due  to  local  and
etastatic  disease  progression.
The  symptom  evaluation  showed  a  moderate  decrease  in
he  reported  median  numerical  scale  for  anxiety  (10--7)  and
ild  reduction  in  pain  (7--6).  No  severe  adverse  events  were
bserved  in  the  next  24  h  after  ECT,  apart  from  mild  local
ain  controlled  with  non-opioid  analgesia.  The  changes  in
he  targeted  lesion  included  painless  skin  necrosis.iscussion
his  is  the  ﬁrst  report  to  assess  the  clinical  efﬁcacy  of  ECT  as
 palliative  treatment  for  PTC.  The  response  was  evaluated
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188  
sing  RECIST  version  1.1.9 There  were  some  difﬁculties
n  the  interpretation  of  the  RECIST  criteria.  Firstly,  some
ncrease  in  the  size  of  the  lesion  could  be  found,  especially
n  the  ﬁrst  few  weeks,  attributed  to  the  local  inﬂammatory
eaction  after  ECT.  In  the  two  cases  reported  as  ‘‘stable
isease’’,  tumor  response  was  observed  in  the  central
art  of  the  tumor,  but  this  is  not  evaluated  in  the  RECIST
riteria.
Patients  reported  a  moderate  improvement  in  the  two
ost  frequent  tumor-derived  symptoms:  local  pain  and
nxiety.  The  treatment  was  well  tolerated,  and  as  the
dministered  dose  of  bleomycin  was  below  the  maximum
olerated  dose,  the  procedure  could  have  been  repeated.
one  of  the  patients  had  the  toxicities  frequently  associated
o  treatments  with  bleomycin.10
PTC  is  commonly  considered  resistant  to  bleomycin
ecause  its  unavailability  to  diffuse  through  the  cell  mem-
rane.  ECT  induces  electroporation  of  the  cell  membrane,
acilitating  the  entrance  of  bleomycin  into  the  cell  from  the
lasma.2,11,12 Once  there,  bleomycin  appears  to  act  strongly
gainst  cell  growth,  inducing  cell  apoptosis  that  can  be
bserved  up  to  several  weeks  after  the  procedure.13
The  present  results  showed  that  ECT  may  be  a  valid
ption  as  palliative  local  treatment  in  PTC  patients  with
ocal  relapse  or  skin  metastases.  The  number  of  patients
nitially  recruited  was  small,  but  that  could  be  explained
ince  papillary  thyroid  cancer  is  a  highly  curable  disease,
nd  because  patients  with  progressive  disease  are  rare  and
ll  the  cases  were  from  a  unique  institution.  Moreover,  other
ystemic  chemotherapy  agents  are  currently  under  investi-
ation  for  such  patients.
It  appears  that  this  procedure  may  have  an  antitumoral
ffect,  particularly  in  lesions  smaller  than  3  cm.5 Another
eta-analysis  published  on  413  patients  with  cutaneous  and
ubcutaneous  tumors  indicated  that  ECT  had  signiﬁcantly
p  < 0.001)  higher  effectiveness  (by  more  than  50%)  than
leomycin  or  cisplatin  alone  and  that  ECT  was  more  effec-
ive  in  sarcoma  than  in  melanoma  or  carcinoma  patients.
o  patients  with  thyroid  carcinoma  were  reported.14 Fur-
her  clinical  trials  with  more  patients  will  clarify  the  role  of
his  procedure.
Also,  it  should  be  determined  whether  a  larger  electrode
ould  enable  reaching  the  tumor  more  extensively,  poten-
ially  leading  to  improved  results.onﬂict of interest
he  authors  declare  no  conﬂicts  of  interest.
1Grau  JJ  et  al.
cknowledgement
his  study  was  supported  by  a  research  project  grant
PI09/90664)  from  the  Spanish  Ministry  for  Science  and  Inno-
ation  and  by  a  research  project  grant  (EC10-067)  from  the
panish  Ministry  of  Health,  Department  of  Pharmacy  and
ealth  Products.
eferences
1. Miklavcˇicˇ D, Mali B, Kos B, Heller R, Serˇsa G. Electrochemother-
apy: from the drawing board into medical practice. Biomed Eng
Online. 2014;13:29.
2. Larkin JO, Collins CG, Aarons S, Tangney M, Whelan M, O’Reily S,
et al. Electrochemotherapy: aspects of preclinical development
and early clinical experience. Ann Surg. 2007;245:469--79.
3. Gargiulo M, Papa A, Capasso P, Moio M, Cubicciotti E, Paras-
candolo S. Electrochemotherapy for non-melanoma head and
neck cancers: clinical outcomes in 25 patients. Ann Surg.
2012;255:1158--64.
4. Landstrom FJ, Nilsson CO, Crafoord S, Reizenstein JA, Adamsson
GB, Lofgren LA. Electroporation therapy of skin cancer in the
head and neck area. Dermatol Surg. 2010;36:1245--50.
5. Mali B, Miklavcic D, Campana LG, Cemazar M, Sersa G, Snoj
M, et al. Tumor size and effectiveness of electrochemotherapy.
Radiol Oncol. 2013;47:32--41.
6. Mir LM, Orlowski S, Belehradek J Jr, Paoletti C. Elec-
trochemotherapy potentiation of antitumour effect of
bleomycin by local electric pulses. Eur J Cancer. 1991;27:68--72.
7. Reinhold U. Electrochemotherapy for primary skin cancer and
skin metastasis related to other malignancies. Anticancer Drugs.
2011;22:711--8.
8. Spratt DE, Gordon Spratt EA, Wu S, DeRosa A, Lee NY, Lacouture
ME, et al. Efﬁcacy of skin-directed therapy for cutaneous metas-
tases from advanced cancer: a meta-analysis. J Clin Oncol.
2014;32:3144--55.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent
D, Ford R, et al. New response evaluation criteria in solid
tumours: revised RECIST guideline (version 1.1). Eur J Cancer.
2009;45:228--47.
0. Albiol S, Grau JJ, Pereira A, Reguart N, Gascon P. Epidemic
hemolytic-uremic syndrome related to bleomycin. Haematolog-
ica. 2001;86:E10.
1. Mir LM, Orlowski S. Mechanisms of electrochemotherapy. Adv
Drug Deliv Rev. 1999;35:107--18.
2. M Mir LM, Orlowski S. The basis of electrochemotherapy. Meth-
ods Mol Med. 2000;37:99--117.
3. Mir LM, Tounekti O, Orlowski S. Bleomycin: revival of an old
drug. Gen Pharmacol. 1996;27:745--8.
4. Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effec-
tiveness of electrochemotherapy: a systematic review and
meta-analysis. Eur J Surg Oncol. 2013;39:4--16.
